Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab Alone or With Pembrolizumab in Advanced Melanoma
NCT06984328Phase 2Terminated
- Sponsor
- Genmab
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of acasunlimab in cutaneous melanoma (CM), sponsored by Genmab. Started Jul 2025; status: terminated.
02
Drugs
acasunlimab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT06984328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984328.